SingleGrowth Hormone

GHRP-2 10mg

A synthetic hexapeptide ghrelin receptor agonist investigated for eliciting pulsatile growth hormone and IGF-1 secretion.

Mechanism

GHRP-2 acts as an agonist at the pituitary and hypothalamic GHS-R1a (ghrelin) receptors, directly stimulating the synthesis and pulsatile release of endogenous growth hormone.

Dosing

Reference protocols document a starting experimental dose of 100 mcg administered once daily on an empty stomach.

Reconstitution

Reconstituting a 10 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 3.33 mg/mL (3,333 mcg/mL).

Storage

Store the unmixed lyophilized powder at -20 °C, and maintain the reconstituted liquid between 2 and 8 °C for up to 28 days without freezing.

Mix & measure GHRP-2 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure GHRP-2 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration3.33mg/mL

Draw volume0.030mL

On the syringe3.00units

Total doses in vial: 100.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	100 mcg (1× daily)	3 units (0.03 mL)
Weeks 3–4	150 mcg (1× daily)	4.5 units (0.045 mL)
Weeks 5–8	200 mcg (1× daily)	6 units (0.06 mL)
Weeks 9–16	200–300 mcg (1× daily)	6–9 units (0.06–0.09 mL)

Reconstitution Steps

1
Aseptically withdraw 3.0 mL of bacteriostatic water using a sterile syringe.
2
Insert the needle into the 10 mg GHRP-2 vial, aiming the flow along the glass wall to minimize agitation and foaming.
3
Gently rotate or roll the vial between the palms until the lyophilized cake is fully dissolved; avoid shaking.
4
Label the vial with the reconstitution date and calculated concentration (~3.33 mg/mL).
5
Store the mixed solution immediately in refrigerated conditions (2–8 °C) protected from light.

Supplies Needed

Peptide Vial

Contains 10 mg of lyophilized GHRP-2 powder for research reconstitution.

Insulin Syringes (U-100)

Calibrated 1 mL, 0.5 mL, or 0.3 mL syringes used to accurately draw micro-volume doses.

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol used to dissolve the peptide cake (3.0 mL required per vial).

Alcohol Swabs

Used to sterilize the rubber vial septum and injection surfaces before handling.

Why researchers study it

GH & IGF-1 secretagogue dynamics

Appetite stimulation and ghrelin signaling

Body composition and fat metabolism markers

Diagnostic evaluation of growth hormone deficiency

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

GHRP-2 (Growth Hormone-Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide categorized as a growth hormone secretagogue. It selectively binds to the growth hormone secretagogue receptor (GHS-R1a), which is the endogenous receptor for ghrelin. In laboratory models, this interaction triggers the anterior pituitary gland to release endogenous growth hormone in a pulsatile manner, downstream influencing systemic IGF-1 production. While clinically approved in specific jurisdictions like Japan strictly as a diagnostic tool for evaluating pituitary insufficiency, GHRP-2 remains an unapproved research compound elsewhere. Unlike more selective secretagogues such as ipamorelin, GHRP-2 demonstrates moderate co-stimulation of secondary neuroendocrine pathways, leading to measurable increases in circulating cortisol and prolactin as well as ghrelin-mediated appetite induction. Laboratory models frequently study GHRP-2 on once-daily administration schedules to prevent rapid receptor desensitization or tachyphylaxis. In investigational settings, it is often evaluated alongside growth hormone-releasing hormone (GHRH) analogues to examine potential synergistic pathways controlling somatotroph secretion.

References

1.Domestic Animal Endocrinology, 2000 — Effects of GHRP-2 on growth hormone release and performance via ghrelin-receptor pathways
2.J Clin Endocrinol Metab, 1997 — Sustained GH and IGF-1 responses during graded GHRP-2 treatment in GH-deficient children
3.Eur J Endocrinol, 1999 — Attenuation patterns and IGF-I kinetics following daily subcutaneous GHRP-2 in healthy males
4.Endocrine, 2002 — Endocrine responses to GHRP-2 and GHRH administration in older adult cohorts
5.American Journal of Men's Health, 2020 — Elevation of serum IGF-1 by growth hormone secretagogues in hypogonadal models
6.Sexual Medicine Reviews, 2018 — Clinical review of growth hormone secretagogue efficacy, selectivity, and safety profiles